Inhibitors assessment in PTPs enrolled in prelicensure trials
| Author . | Brand . | Sample . | FVIII level . | ED . | Inhibitors . |
|---|---|---|---|---|---|
| White et al23 | Recombinate | 69 | < 0.05 | NR | 0 |
| Schwartz et al24 | Kogenate | 86 | NR | NR | 1 |
| Abshire and Brackmann25 | Kogenate-FS | 73 | < 0.02 | > 100 | 0 |
| Courter and Bedrosian26 | Refacto | 113 | < 0.02 | > 30/y | 1 |
| Tarantino et al27 | Advate | 108 | < 0.01 | > 150 | 1 |
| Recht et al28 | RefactoAF | 204 | < 0.02 | > 150 | 3 |
| Author . | Brand . | Sample . | FVIII level . | ED . | Inhibitors . |
|---|---|---|---|---|---|
| White et al23 | Recombinate | 69 | < 0.05 | NR | 0 |
| Schwartz et al24 | Kogenate | 86 | NR | NR | 1 |
| Abshire and Brackmann25 | Kogenate-FS | 73 | < 0.02 | > 100 | 0 |
| Courter and Bedrosian26 | Refacto | 113 | < 0.02 | > 30/y | 1 |
| Tarantino et al27 | Advate | 108 | < 0.01 | > 150 | 1 |
| Recht et al28 | RefactoAF | 204 | < 0.02 | > 150 | 3 |
ED indicates exposure day; NR, not reported; and PTP, previously treated patients.